Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 38 Head & Neck 20 Gastrointestinal 17 Thoracic 12 Endocrine 12 CNS 12 Tumor-Agnostic 7 Other hematologic neoplasm 6 Plasma cell 5 Lymphoid 5 Genitourinary 4 Sarcoma 3 Myeloid 3 Other solid neoplasm 2 Gynecologic 2 Breast 2 Other neoplasm 1 Other 1 Classical hematology 1

Conditions

Rare Malignant Neoplasm 1

Interventions

Surveys and Questionnaires 9 Cyclophosphamide 9 Whole-Body Irradiation 7 Biopsy 7 fludarabine phosphate 6 Peripheral Blood Stem Cell Transplantation 6 Educational Status 6 Early Intervention, Educational 6 Busulfan 6 Methotrexate 5 Methods 5 Immunohistochemistry 5 Epoetin Alfa 5 Tacrolimus 4 Mycophenolic Acid 4 Interviews as Topic 4 Gene Expression Profiling 4 Decitabine 4 Cyclosporine 4 Celecoxib 4 Antilymphocyte Serum 4 fludarabine 3 Sirolimus 3 Radiotherapy 3 Paclitaxel 3 Microarray Analysis 3 Melphalan 3 Magnetic Resonance Spectroscopy 3 Imiquimod 3 Fentanyl 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × trametinib × Other neoplasm × Clear all

NCT06119789 2025-03-26

MATRIX-Rare

Oslo University Hospital

Phase 2 Recruiting

Rare Malignant Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon ⚡